Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968938 | 0.84 | POLB (0.48) | POLBLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL19422787 | 0.84 | NPC1 (0.49) | POLBLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL3968933 | 0.83 | POLB (0.47) | POLBLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL14177257 | 0.83 | POLB (0.47) | POLBLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL13490840 | 0.82 | LTB4R (0.44) | LMNAKDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL6971126 | 0.80 | ALOX15 (0.45) | POLBLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL12468374 | 0.80 | CYP1A2 (0.47) | POLBLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL6971124 | 0.80 | ALOX15 (0.45) | POLBLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL8936165 | 0.79 | POLB (0.42) | POLBLMNAMEN1KMT2AKDM4E | |
| SCHEMBL7252416 | 0.79 | NPC1 (0.48) | POLBLMNAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126995-B2 | Method for catalytic asymmetric synthesis of optically active isoxazoline compound and optically active isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20140350261-A1 | METHOD FOR CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE ISOXAZOLINE COMPOUND, AND OPTICALLY ACTIVE ISOXAZOLINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-11-27 | — | — | US | disclosed |
| EP-1027332-B1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | DUAN JINGWU (US) | 2003-07-17 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | POLB 1570/4885LMNA 3025/4885L3MBTL1 3833/4885 |
| US-20140350261-A1 | METHOD FOR CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE ISOXAZOLINE COMPOUND, AND OPTICALLY ACTIVE ISOXAZOLINE COMPOUND | CYP3A7, CYP2A7, CYP8B1 | POLB 326/4885LMNA 1006/4885L3MBTL1 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.